395 related articles for article (PubMed ID: 32732848)
1. Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice.
Cucchiari D; Molina-Andujar A; Montagud-Marrahi E; Revuelta I; Rovira J; Ventura-Aguiar P; Piñeiro GJ; De Sousa-Amorim E; Esforzado N; Cofán F; Torregrosa JV; Ugalde-Altamirano J; Ricart MJ; Centellas-Pérez FJ; Solè M; Martorell J; Ríos J; Campistol JM; Diekmann F; Oppenheimer F
Transplantation; 2020 Aug; 104(8):1686-1694. PubMed ID: 32732848
[TBL] [Abstract][Full Text] [Related]
2. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
3. Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis.
Montero N; Quero M; Melilli E; Pérez-Sáez MJ; Redondo-Pachón D; Bestard O; Crespo M; Cruzado JM; Pascual J
Transplantation; 2019 Oct; 103(10):2031-2056. PubMed ID: 31343574
[TBL] [Abstract][Full Text] [Related]
4. Combination of calcineurin and mTOR inhibitors in kidney transplantation: a propensity score analysis based on current clinical practice.
Cucchiari D; Ríos J; Molina-Andujar A; Montagud-Marrahi E; Revuelta I; Ventura-Aguiar P; Piñeiro GJ; De Sousa-Amorim E; Esforzado N; Cofán F; Torregrosa JV; Ugalde-Altamirano J; Ricart MJ; Rovira J; Torres F; Solè M; Campistol JM; Diekmann F; Oppenheimer F
J Nephrol; 2020 Jun; 33(3):601-610. PubMed ID: 31853792
[TBL] [Abstract][Full Text] [Related]
5. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Nashan B; Schemmer P; Braun F; Dworak M; Wimmer P; Schlitt H
Trials; 2015 Mar; 16():118. PubMed ID: 25873064
[TBL] [Abstract][Full Text] [Related]
7. Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study.
Tedesco-Silva H; Pascual J; Viklicky O; Basic-Jukic N; Cassuto E; Kim DY; Cruzado JM; Sommerer C; Adel Bakr M; Garcia VD; Uyen HD; Russ G; Soo Kim M; Kuypers D; Buchler M; Citterio F; Hernandez Gutierrez MP; Bernhardt P; Chadban S;
Transplantation; 2019 Sep; 103(9):1953-1963. PubMed ID: 30801548
[TBL] [Abstract][Full Text] [Related]
8. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
[TBL] [Abstract][Full Text] [Related]
9. Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients.
de Boer SE; Sanders JSF; Bemelman FJ; Betjes MGH; Burgerhof JGM; Hilbrands L; Kuypers D; van Munster BC; Nurmohamed SA; de Vries APJ; van Zuilen AD; Hesselink DA; Berger SP
BMC Nephrol; 2021 Jun; 22(1):208. PubMed ID: 34078323
[TBL] [Abstract][Full Text] [Related]
10. De Novo Donor-Specific Antibody Formation in Tacrolimus-Based, Mycophenolate Versus Mammalian Target of Rapamycin Immunosuppressive Regimens.
Mithani Z; Gralla J; Adebiyi O; Klem P; Cooper JE; Wiseman AC
Exp Clin Transplant; 2018 Feb; 16(1):23-30. PubMed ID: 28332959
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
[TBL] [Abstract][Full Text] [Related]
12. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
13. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
15. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Follow-Up of De Novo Use of mTOR and Calcineurin Inhibitors After Kidney Transplantation.
de Paula MI; Medina Pestana JO; Nicolau Ferreira A; Pontello Cristelli M; Fabiano Franco M; Aguiar WF; Tedesco-Silva H; Rosso Felipe C
Ther Drug Monit; 2016 Feb; 38(1):22-31. PubMed ID: 26121616
[TBL] [Abstract][Full Text] [Related]
17. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
Gustafsson F; Andreassen AK; Andersson B; Eiskjær H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
Transplantation; 2020 Jan; 104(1):154-164. PubMed ID: 30893292
[TBL] [Abstract][Full Text] [Related]
18. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
[TBL] [Abstract][Full Text] [Related]
19. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
20. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
Pascual J; Berger SP; Witzke O; Tedesco H; Mulgaonkar S; Qazi Y; Chadban S; Oppenheimer F; Sommerer C; Oberbauer R; Watarai Y; Legendre C; Citterio F; Henry M; Srinivas TR; Luo WL; Marti A; Bernhardt P; Vincenti F;
J Am Soc Nephrol; 2018 Jul; 29(7):1979-1991. PubMed ID: 29752413
[No Abstract] [Full Text] [Related]
[Next] [New Search]
